Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
1don MSN
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
Q1 2026 Management View "Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency create better medicines for ...
Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, Recursion Pharmaceuticals reported its financial results for Q4 and the full ...
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results